EGFR and non-small cell lung carcinoma: For example, despite tyrosine kinase inhibitors (TKIs) targeting EGFR can effectively extend the survival time and improve the life quality of NSCLC patients; only about 10%‐20% patients with non‐EGFR mutation benefitted from it.44, 45